Suggestions(1)
Exact(14)
"Past TB" was defined as culture-positive pulmonary TB in which completion of a 6-month course of treatment led to culture-negative sputa.
This correlates with an earlier report of histopathologically proven ocular TB, in which 40% of patients had negative TST and 57% had normal chest films [13].
The clinical presentation in our patients was predominantly posterior uveitis (retinal vasculitis and MSC) or panuveitis, unlike an earlier report on presumed ocular TB, in which nearly half (45.1%) of the patients had anterior or intermediate uveitis[5].
In this report we present a case of isolated colonic TB in which the initial diagnostic workup suggested CD.
Differently from TB, in which transbronchial needle aspiration (TBNA) has a possible role in diagnosis, only few data exist about NTM infection.
This is particularly true for chronic infections like HIV or TB, in which pathogens and immune system coexist in a long struggle.
Similar(46)
3 The term "totally drug-resistant TB" (TDR) was proposed to define TB cases with a resistance profile beyond XDR-TB, in which the strain would be virtually resistant to all available first- and second-line drugs.
South Africa – which has the world's seventh-highest rates of TB – is currently building nine new TB wards in which airborne infection control is the overriding design priority.
EBA studies assess the early phase of TB treatment, in which a drug's ability to kill metabolically active bacilli is being evaluated [31].
Of the 51 TB investigations in which CDC participated during 2002 2008, a total of 27 met the inclusion criteria.
In addition, CPT remained an important factor in reduction of mortality during TB treatment, in which patients without CPT were at a 3.03 times higher risk of mortality (95% CI: 1.58, 5.79).
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com